R.A. Session II

R.A. Session II is a declared insider at 2 companies; the most frequent names are Taysha Gene Therapies, Inc. and AveXis, Inc. Over a trading history stretching from 13 March 2018 to 13 July 2023, the count stands at 11 filings.

The open-market side counts 2 purchases for €471k alongside 6 sales for €354k. The net balance comes to €116k on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant. So far in 2023, the count stands at no purchases and 6 sales.

On 14 July 2023 came the latest disclosure, an open-market sale for €3,333 in Taysha Gene Therapies, Inc. The most recent open-market purchase was published on 8 December 2021, 1,796 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.